Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813468 | 0.98 | CES2 (0.46) | CES2CES1HDAC8HDAC6NOS2 | |
| SCHEMBL29056275 | 0.95 | — | — | |
| SCHEMBL10683868 | 0.90 | KMT2A (0.33) | — | |
| SCHEMBL28735265 | 0.90 | — | — | |
| SCHEMBL6248920 | 0.86 | CES2 (0.39) | CES2CES1HDAC8HDAC6NOS2 | |
| SCHEMBL29165191 | 0.84 | SMN1; SMN2 (0.38) | CES2CES1HDAC8HDAC6NOS2 | |
| SCHEMBL29056312 | 0.84 | CES2 (0.42) | CES2CES1HDAC8HDAC6NOS2 | |
| SCHEMBL29056296 | 0.81 | CES2 (0.33) | CES2CES1NOS2SMN1; SMN2 | |
| SCHEMBL7714802 | 0.78 | CES2 (0.43) | CES2CES1HDAC8HDAC6NOS2 | |
| SCHEMBL23727961 | 0.77 | CES2 (0.43) | CES2CES1HDAC8HDAC6NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640157-A | METTL3 inhibitor and composition thereof and application of METTL3 inhibitor and composition thereof in medicine | 海思科医药集团股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-118339168-A | Fused ring heterocyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-116640157-A | METTL3 inhibitor and composition thereof and application of METTL3 inhibitor and composition thereof in medicine | 海思科医药集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-101801972-A | Pyrazolo [1,5-A]pyrimidines as inhibitors of stearoyl-coA desaturase | INOVACIA AB | 2010-08-11 | — | — | CN | disclosed |
| EP-2137187-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | Inovacia AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | disclosed |
| EP-0686636-B1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA CO (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5840895-A | INTERMEDIATES FOR ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5686442-A | ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0686636-A1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | CES2 1198/4885CES1 120/4885HDAC8 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.